Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01461382|
Recruitment Status : Completed
First Posted : October 28, 2011
Last Update Posted : October 28, 2011
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Is a one-year intervention with Treadmill Desks associated with increased employee daily physical activity and decreased sedentariness.
36 employees with sedentary jobs (87 + 27 kg, BMI 29 + 7 kg/m2) used a Treadmill Desk for one year. Daily Physical Activity, work performance, body composition, and blood variables were measured at Baseline and 6 and 12 months after the Treadmill Desk intervention.
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Other: Treadmill Desks||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
Experimental: Phase I
Entered Study May 2008.
Other: Treadmill Desks
Treadmill Desk were installed in subjects personal workspace.
Experimental: Phase II
Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
Other: Treadmill Desks
Treadmill desks were installed in subjects personal workspace six months after phase I started.
- Daily Physical Activity [ Time Frame: 1 year ]Measured for all waking hours using tri-axial accelerometry.
- Body Weight [ Time Frame: baseline, 6 months, 12 months ]
- Body Composition [ Time Frame: baseline, 6 months, 12 months ]
- Venous blood [ Time Frame: baseline, 6 months, 12 months ]
- Work performance [ Time Frame: baseline, 6 months, 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Subjects will be recruited regardless of race/ethnicity.
Definite termination criteria.
- Request by subject to leave study.
- Evidence of deliberate non-compliance (e.g.; placing activity instruments on another individual, deliberate destruction of instruments).
- Alcohol abuse; elicit drug abuse.
- Development of chronic condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., Grave's disease, hypothyroidism, rheumatoid arthritis requiring steroids or limiting mobility, congestive cardiac failure, neurological disorder such as multiple sclerosis or stroke).
- Development of acute condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., motor vehicle accident with multiple fractures, myocardial infarction, major depression).
Potential termination criteria.
Development of acute or chronic condition that may impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate. Subjects will be reviewed on a subject-by-subject basis and will be reported to the Safety-Monitoring Panel. Specific action plans are pre-assigned for:
- Diabetes (two fasting plasma glucose values >126 mg/dl). Here, glycosylated hemoglobin will be measured three monthly (by the study) and subjects referred to their local physician for preventative screening. Subjects will be excluded from further study with any glycosylated hemoglobin value of >8% or symptomatic hyperglycemia.
- Depression or low mood. Here, all patients will be asked to be evaluated by their primary care physician and if appropriate referred to a psychiatrist. The opinion of the psychiatrist will be used to determine continuance or termination in the protocol.
This does not represent a comprehensive listing of criteria or causes. All subjects who withdraw or whom are withdrawn from the study or whom are considering/being considered for withdrawal will be referred to the Safety-Monitoring Panel. These subjects' data will be scrutinized (whether terminated or not) separately to assess for association of intervention with a specific adverse outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01461382
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||James A Levine, MD PhD||Mayo Clinic|
|Responsible Party:||James Levine, Professor of Medicine, Mayo Clinic|
|Other Study ID Numbers:||
|First Posted:||October 28, 2011 Key Record Dates|
|Last Update Posted:||October 28, 2011|
|Last Verified:||October 2011|
Body Weight Changes